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ABSTRACT
The optimal postremission treatment for elderly patients with acute myelogenous leukemia (AML) is presently
unknown, but recent studies report the feasibility of autologous stem cell transplantation in this population. To
better understand the long-term outcome of autologous transplantation in AML patients >60 years of age, we
evaluated high-dose chemoradiotherapy preparative conditioning followed by transplantation of peripheral
blood progenitor cells procured after a single cycle of cytarabine-based consolidation chemotherapy as
postremission therapy in 27 patients aged 60 to 71 years (median age, 65 years) with newly diagnosed AML in
first complete remission (CR). The median follow-up from CR for all patients was 13.6 months (range,
6.0-123.1 months). The median follow-up from remission for surviving patients was 81 months (range,
41.4-123.1 months). Seven patients are alive in continuous CR, 19 died from relapse, and 1 died as a result of
treatment-related infection. Leukemia-free survival and overall survival are 10.3 and 13.4 months, respectively.
Actuarial leukemia-free and overall survival at 3 years are 25%  9% and 28%  9%, respectively. Our results
demonstrate that autologous transplantation of peripheral blood progenitor cells is well tolerated and feasible
for patients >60 years of age with AML in first CR. Future investigation should focus on a randomized study
evaluating a larger group of elderly patients in first CR comparing autologous stem cell transplantation with
conventional cytarabine-based consolidation chemotherapy to identify the optimal postremission therapy.
© 2006 American Society for Blood and Marrow Transplantation
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Despite reports of improved response and leukemia-
ree survival (LFS) for subgroups of younger patients
ith acute myelogenous leukemia (AML), advanced
ge remains a signiﬁcant adverse prognostic factor.
he elderly represent a large proportion of AML
atients, but most single- and multi-institutional stud-
es evaluating postremission therapy either exclude
atients 60 years entirely or include only a fraction
f older patients [1,2]. In addition to a higher inci-
ence of treatment-related complications, the biology t
66f AML in older patients is often characterized by
dverse cytogenetic features, a history of antecedent
yelodysplasia, and phenotypic features predictive
f brief LFS. Currently, there is no consensus on
he optimal postremission therapy for older patients.
ome regimens, such as allogeneic bone marrow
ransplantation, are restricted on the basis of patient
ge because of a high risk of transplant-related mor-
ality attributed to graft-versus-host disease. Recent
tudies suggest that autologous stem cell transplanta-
ion is feasible in some older patients with acceptable
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Boxicity and a relatively low rate of transplant-related
ortality [3-8]. To better understand the long-term
utcome of autologous transplantation in older pa-
ients, we evaluated high-dose chemoradiotherapy
reparative conditioning followed by peripheral blood
rogenitor cell (PBPC) transplantation as postremis-
ion therapy in 27 patients aged 60 years with newly
iagnosed AML in ﬁrst complete remission (CR).
ATIENTS AND METHODS
Twenty-seven adult patients (median age, 65
ears; range, 60-71 years) were enrolled in 3 sequen-
ial Acute Leukemia Protocol studies conducted by
he University of California-Los Angeles School of
edicine from November 1992 to March 2002. Data
ere analyzed as of June 1, 2005. These studies were
pproved by the University of California-Los Angeles
fﬁce for the Protection of Research Subjects, and all
atients gave written informed consent to participate.
he diagnosis of AML was made according to French-
merican-British criteria [9]. De novo AML was de-
ned as no documented hematologic abnormality
dentiﬁed 2 months before diagnosis. Preleukemia
as deﬁned as ineffective hematopoiesis documented
2 months before the diagnosis of AML by either an
bnormal bone marrow evaluation or an otherwise
nexplained peripheral blood cytopenia [10,11].
aryotype was interpreted as follows: (1) normal, that
s, diploid; (2) abnormal but favorable, that is, t(8;21)
r abnormalities of 16q; (3) abnormal and unfavorable
ie, trisomy 8, abnormalities of chromosome 5 and/or
, and abnormality of chromosome 11 or multiple [3
bnormalities] or complex translocation); and (4) ab-
ormal (all others) [9]. Patients with acute promyelo-
ytic leukemia (French-American-British M3) with or
ithout t(15;17) were not eligible. Patients received
nduction chemotherapy consisting of either cytara-
ine 100 to 200 mg/m2 by continuous infusion for 5 to
days and idarubicin 10 to 13 mg/m2/d  3 or
aunorubicin 45 to 60 mg/m2/d by intravenous (IV)
olus for 3 days. Patients received a second course of
nduction chemotherapy on or after day 21 if residual
eukemia was found in blood or bone marrow. Com-
lete hematologic remission was deﬁned by the crite-
ia of Ellison et al. [12].
Patients received high-dose cytarabine–based con-
olidation treatments administered in a single course,
hich was started a median of 4 weeks after achievement
f CR. Consolidation chemotherapy consisted of cyt-
rabine 2 g/m2 administered as a 2-hour IV infusion
very 12 hours for 4 days and mitoxantrone 10 mg/m2
y IV bolus per day for 3 days. There was no dose
djustment for advanced age. Recombinant human
ranulocyte colony-stimulating factor was adminis-
ered at 5 g/kg subcutaneously or IV over 30 minutes l
B&MTeginning 1 day after completion of consolidation and
ontinuing until the completion of stem cell leuka-
heresis. Eleven patients received interleukin 2 both
fter consolidation chemotherapy, to help mobilize
BPCs for procurement, and after autologous trans-
lantation as a form of posttransplantation mainte-
ance therapy [13]. All patients underwent autologous
tem cell transplantation after preparative condition-
ng with 11.25 Gy of total body irradiation given in 5
ractions over 2.5 days (before 1998) or 8 fractions
after 1998) and cyclophosphamide 60 mg/kg/d by IV
nfusion over 1 hour daily for 2 days. All patients
eceived mesna 60 mg/kg/d by continuous IV infusion
t the start of cyclophosphamide and continuing for
4 hours after the last dose. After completion of trans-
lantation, no maintenance cytotoxic therapy or other
ntileukemia therapy was administered until relapse.
Progenitor cell apheresis was begun after an ab-
olute neutrophil count 1500/L was achieved dur-
ng the recovery phase from consolidation therapy.
ontinuous-ﬂow leukapheresis was performed daily
n weekdays with a Cobe Spectra (Cobe, Lakewood,
O) until a total nucleated cell count of 3  108/kg
nd/or a CD34 cell count of 1  106/kg was ob-
ained. Blood volume processed per run was 10 L at a
ow rate of 50 to 70 mL/min. Platelet and erythrocyte
ractions were reinfused continuously. The ﬁnal
pheresis product was centrifuged at 400g, concen-
rated to 1  108 cells per microliter, and cooled to
°C. Cytogenetics were analyzed on an aliquot of the
eukapheresis collection in all patients undergoing
rogenitor cell procurement, as previously described
14]. Cell counts were performed with a Coulter
ounter (Coulter Electronics, Hialeah, FL). Samples
ere run on a FACScan ﬂow cytometer (Becton Dick-
nson, San Jose, CA), and after 1994, CD34 cells
ere deﬁned with histogram analysis by using the
ntire live-cell population. Supportive care for gran-
locytopenic patients consisted of reverse isolation
n single rooms and treatment with oral nonabsorb-
ble antibiotics, including nystatin and either nor-
oxacin or ciproﬂoxacin. Febrile granulocytopenic pa-
ients received imipenem, cefoperazone/sulbactam, or
ther broad-spectrum antibacterial antibiotics. Pa-
ients with documented or suspected fungal infec-
ions were treated with empiric amphotericin B or
uconazole. Random or single-donor platelet trans-
usions were administered to maintain a platelet
ount of 10  109/L. Erythrocytes were transfused
o maintain a hematocrit 27%. Hematopoietic
rowth factors were not administered after autolo-
ous transplantation.
The date of diagnosis of AML and the date of
emission were deﬁned by the date of the diagnostic
one marrow studies. Patient survival and LFS from
he time of remission were computed by the product-
imit method of Kaplan and Meier [15].
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4ESULTS
Twenty-seven patients with AML in CR1 under-
oing autologous progenitor cell transplantation were
ntered into the study. The baseline characteristics of
hese patients at diagnosis are listed in Table 1. The
edian age was 65 years (range, 60-71 years). Seven-
een patients had normal karyotypes, whereas 8 had
bnormal cytogenetic studies, including 1 patient with
onosomy 7. In 2 patients, karyotypes could not
e determined. Eight patients had an antecedent
ematologic disorder. Engraftment was successfully
chieved in 26 patients (96%). The median number of
ays to an absolute neutrophil count 500/L and
latelets 20 000/L were 16 days (range, 11-36
ays) and 20 days (range, 3-60 days), respectively.
oxicity
Treatment-related death occurred in 1 patient
econdary to complications of pneumonia. Treatment-
able 1. Patient Characteristics
Variable Data
o. patients 27
ex (M/F) 18/9
edian age (y) 65
ge range (y) (60–71)
ntecedent hematologic disorder 8 (29%)
hromosomal abnormality (yes/no/unknown) 8/17/2
aryotype
Normal 17
Abnormal (favorable) 2
Abnormal (unfavorable) 5
Abnormal (other) 1
Unknown 2
AB subtype
Biphenotypic 0
M0 1
M1 9
M2 5
M3 0
M4 9
M5 1
M6 1
Unknown 1
AB indicates French-American-British classiﬁcation.
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68elated complications also included mucositis in 11
atients, zoster infection in 4 patients, bacteremia in 4
atients, paroxysmal atrial ﬁbrillation in 2 patients,
epatic veno-occlusive disease in 1 patient, fungal
neumonia in 1 patient, Clostridium difﬁcile infection
f the colon in 1 patient, and Sweet syndrome in 1
atient.
urvival
Twenty patients died by the date of analysis: 19
rom relapse of AML and 1 from complications of
neumonia. Seven patients were alive and leukemia–
ree at the end of the study. The median follow-up
rom CR for all patients was 13.4 months (range,
.0-123.1 months). The median follow-up from re-
ission for surviving patients was 81 months (range,
1.4-123.1 months). The median time from achieve-
ent of CR to transplantation was 2.9 months (range,
.6-4.1 months). The median time to relapse was 8.6
onths (range, 3.3-22.7 months). Median LFS and
verall survival were 10.3 months (range, 3.3-123.1
onths) and 13.4 months (range, 3.9-123.1 months),
espectively, from CR. The median LFS and overall
urvival from transplantation were 7.1 months (range,
.6-121.5 months) and 9.8 months (range, 1.8-121.5
onths), respectively. Actuarial LFS at 3 years was
5%  9%, and actuarial overall survival at 3 years
as 28%  9% (Figures 1 and 2).
ISCUSSION
Many clinical trials evaluating postremission strat-
gies for AML have excluded older patients on the
asis of comorbid conditions and aggressive disease
iology. Studies of high-dose cytarabine–based con-
olidation chemotherapy, as well as myeloablative ap-
roaches, have been infrequently applied to patients
ver the age of 60. Many elderly patients have adverse
ytogenetic characteristics, a history of antecedent
yelodysplasia, and a high likelihood of multidrug
esistance protein expression. Frequently, there are
henotypic features predictive of a poor response to
ree Survival 
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9
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Bnduction chemotherapy and brief LFS [16,17]. Older
atients are also often excluded from many phase II
rials that tend to enroll younger patients with more
avorable disease characteristics on the basis of the
ssumption that younger patients will derive greater
eneﬁt from dose-intensive treatment. In addition,
here is a general view that older patients cannot
olerate intensive doses of consolidation chemother-
py or transplantation conditioning. Allogeneic trans-
lantation is uniformly withheld from older individu-
ls on the basis of a high risk of graft-versus-host
isease.
Most AML patients, however, are over age 60, and
here is an age-related increase in leukemia incidence
nd prevalence that argues for studying postremission
trategies in this population [17]. One approach to
ostremission therapy includes the use of high-dose
ytarabine. The Cancer and Leukemia Group B per-
ormed a study in adult AML patients by using high-
ose, intermediate-dose, or low-dose cytarabine as
ostremission therapy. In this trial, 596 patients in CR
ere randomized to consolidation treatment with 4
ycles of conventional-dose cytarabine (100 mg/m2/d
5 days), intermediate-dose cytarabine (400 mg/
2/d  5 days) or high-dose cytarabine (3 g/m2 in a
otal of 6 doses over 5 days). The 4-year disease-free
urvival rate was 44% in those who received high-dose
ytarabine, compared with 24% in those who received
onventional-dose cytarabine. However, patients over
ge 60 did poorly regardless of the type of consolida-
ion they received; only 14% achieved durable remis-
ion, although only one third of patients in this age
roup received all 4 courses of high-dose cytarabine,
rimarily as a result of central nervous system toxicity
18]. Furthermore, a subsequent Cancer and Leuke-
ia Group B trial comparing modiﬁed high-dose cyt-
rabine plus mitoxantrone with standard lower-dose
ytarabine failed to show any additional beneﬁt in
lderly AML patients [19]. Hence, conventional che-
otherapy given to elderly AML patients is associated
Ov
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Figure 2.ith a high relapse rate, and high-dose chemotherapy p
B&MTs typically not tolerated well secondary to treatment-
elated toxicity.
Several randomized, prospective trials have com-
ared the various postremission therapies in younger
dults with AML and have shown that autologous
ransplantation is associated with a lower relapse rate
han conventional chemotherapy. The US Intergroup
tudy, for example, revealed that the relapse rate after
years was 61% in patients treated with high-dose
ytarabine, compared with 48% in those treated with
utologous transplantation [20]. Patients treated with
igh-dose chemotherapy, however, were found to
ave a slightly improved overall survival than those
reated with autologous transplantation, primarily be-
ause they were able to undergo salvage autologous
one marrow transplantation (ABMT) or allogeneic
ransplantation in second CR. These results, however,
o not necessarily suggest that elderly patients would
eneﬁt from receiving conventional chemotherapy
nce they entered CR1, because they would not be
deal candidates for autologous transplantation if they
elapsed and were unable to achieve CR2.
Recent studies have demonstrated that ABMT is
easible in the elderly and is associated with a low
reatment-related morbidity and acceptable toxicity,
hus providing a more attractive treatment option to
his patient population. The European Group for
lood and Marrow Transplantation studied 111 AML
atients in CR1 over the age of 50 years treated with
BMT and compared them with 786 patients under
he age of 50 [21]. They noted that the probability of
FS at 4 years for patients aged50 years was 34%
%, compared with 43%  2% for patients less than
0 years of age, with an overall survival probability of
5%  6% and 48%  2%, respectively (P  .004).
espite a signiﬁcant difference in LFS and overall
urvival in the 2 groups, no difference was observed
etween the 2 groups in terms of relapse (52%  7%
ersus 50%  2%, respectively) [21]. Several other
roups have reported the results of ABMT for AML
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4atients (median age, 64 years) with ABMT and noted
hat the median LFS and overall survival from diag-
osis were 19 and 14 months, respectively. Gorin et al.
4] studied a much larger population of 193 patients in
R1 over the age of 60 and demonstrated that overall
urvival and LFS at 3 years were 47%  5% and 36%
5%, respectively, whereas the transplant-related
ortality was 15%  4% and the relapse incidence
as 58%  5%. In addition, they noted that patients
ho received stem cells harvested from the bone mar-
ow as opposed to the peripheral blood had a lower
ate of relapse: 44%  11% compared with 63% 
% (P  .04). The likely reason for this difference has
een attributed to collection of stem cells immediately
fter induction of remission, as opposed to collection
fter several rounds of consolidation therapy or in vivo
urging, thus leading to contamination of the graft by
obilized leukemia progenitors. Despite the decrease
n relapse incidence in patients who received stem cell
arvested from bone marrow, transplanting stem cells
rom peripheral blood has gained popularity because
f faster hematopoietic recovery. Such transplanta-
ions are safer in older patients. Moreover, the use of
ntermediate- or high-dose cytarabine has been used
s mobilization to reduce the possible contamination
f transplanted stem cells with leukemia cells. This
pproach has been well tolerated and found to be
ssociated with a lower relapse rate compatible with
he relapse rate observed in patients undergoing stem
ell transplantation from marrow. Nevertheless, the
se of purging techniques to improve the outcome of
utologous stem cell transplantation in AML is not
ell deﬁned, and no randomized study has been per-
ormed to provide conclusive data on whether it de-
reases LFS.
In our study, autologous transplantation of PBPCs
rocured after high-dose cytarabine–based consolida-
ion and infused after myeloablative chemoradiother-
py preparative conditioning as postremission therapy
as evaluated in 27 patients aged 60 to 71 years
median age, 65 years) with newly diagnosed AML in
rst CR. Follow-up for surviving patients was 81
onths (range, 41.4-123.1 months), thus making this
tudy one of the longest in terms of follow-up. The
atients in our study tolerated a regimen of high-dose
ytarabine 2 g/m2 as a form of consolidation treatment
ith mitoxantrone. No posttransplantation granulo-
yte colony-stimulating factor was administered; how-
ver, 11 patients received interleukin 2 after neutrophil
ecovery as a form of posttransplantation maintenance
herapy. After high-dose chemoradiotherapy and au-
ologous transplantation, successful engraftment oc-
urred in 26 patients (96%), thus conﬁrming that
utologous PBPC transplantation is feasible in this
opulation. Moreover, hematopoietic reconstitution
as swift and comparable to that in younger patients
reated in the same manner. One patient died from a
70reatment-related complications, and toxicity, includ-
ng cases of mucositis and infection, was not observed
n most patients during the peritransplantation period.
hese results support the acceptable toxicity proﬁle
eported in other studies and help support the use of
igh-dose therapy in the elderly. Actuarial LFS and
verall survival at 3 years were 25% 9% and 28%
%, respectively. Although the long-term survival
ata compare less favorably to those in younger pa-
ients treated with ABMT, this form of treatment
epresents a form of postremission therapy that is
vailable to older patients with acceptable toxicity and
relatively low rate of transplant-related morbidity.
Our results show that autologous transplantation
f PBPCs procured after a single cycle of cytarabine-
ased consolidation chemotherapy is well tolerated
nd feasible for patients older than 60 years of age
ith AML in ﬁrst CR. Although there may be an
lement of selection in the accrual of older patients to
eukemia trials in an academic medical center, the
hanging demographics of ﬁtness in the elderly sug-
est that, at least in the population we studied, dose-
ntensive treatment may be well tolerated. Therefore,
BMT should not be conﬁned solely to a population
f patients aged 60 years and younger simply because
ge is an independent predictor of disease recurrence.
ong-term survival is possible in an elderly population
reated with ABMT. Future investigation should focus
n evaluating a larger group of elderly patients in ﬁrst
R comparing autologous stem cell transplantation
ith conventional cytarabine consolidation chemo-
herapy in randomized studies to identify optimal pos-
remission therapy.
Other transplantation modalities that have been
ecently used in the elderly include nonmyeloablative
llogeneic transplantation. This form of therapy takes
dvantage of the properties associated with allogeneic
ransplantation, such as the graft-versus-tumor effect,
ut is a less toxic form of treatment because high-dose
hemotherapy is not used as preparative therapy. A
ew studies have reported successful engraftment in
atients who received either matched or unmatched
onor stem cells after a ﬂudarabine-based preparative
onditioning regimen. Long-term survival has not
een properly evaluated in these patients, but 1 study
y Bertz et al. [22] reported a 1-year nonrelapse mor-
ality of 22% and a 1-year survival rate of 68%. Fur-
her studies need to be performed to gain more expe-
ience with this approach.
Although transplantation serves as one broad form
f postremission therapy in the elderly population
ith AML that confers, for some, a state of minimum
esidual disease, newer forms of therapy are currently
eing developed and evaluated. Perhaps the most
romising class of new agents includes inhibitors of
ignal transduction designed to inhibit proliferation
nd survival signals within leukemia cells. One exam-
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Ble is the farnesyl transferase inhibitors, which target
arnesyl protein transferase involved in the downregu-
ation of overexpressed molecules, including RAS, mi-
ogen-activated protein kinase, or AKT, that promote
he proliferation and survival of cells observed in he-
atologic malignancies. Molecular inhibitors of Flt-3
yrosine kinase, an enzyme that plays an important
ole in the generation of cellular proliferation signals,
s another attractive target in the treatment of AML.
linical trials are currently under way to investigate
he potential therapeutic effects in AML patients. In-
orporating newer agents after autologous transplan-
ation should be evaluated as maintenance therapy in
osttransplantation patients in an attempt to reduce
he risk of relapse.
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